文献速递白血病

IDO1相关免疫基因特征可预测急性髓系白血病总生存

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

该研究基于982例初诊非早幼粒细胞AML患者的公开数据,分析骨髓免疫微环境相关基因的预后价值。研究发现BIN1与IDO1表达呈负相关且各自预测总生存,将PLXNC1纳入IDO1-BIN1评分形成强效免疫基因特征,尤其在接受化疗的患者中预测生存。基于差异表达基因进一步构建的7基因和10基因免疫特征高度预测生存并与AML突变状态相关。

要点

  • IDO1与BIN1表达负相关,二者各自可预测AML总生存。
  • PLXNC1与IDO1互作最强且保留最强预后价值,纳入后形成2基因IDO1-BIN1评分。
  • 基于差异表达基因构建的7基因和10基因免疫特征高度预测生存并与诊断时AML突变状态相关。

核心结论

  • IDO1是构建预测AML患者生存的免疫基因特征的关键分子。
  • 免疫生物标志物有望纳入当前AML分类和预后算法。

研究设计与样本

  • 从公开数据集检索982例初诊非早幼粒细胞AML患者的生物学和临床数据,使用既定计算流程分析。
  • 采用NanoString nCounter平台分析24份诊断骨髓样本的靶向转录组图谱。

主要发现

  • BIN1与IDO1表达呈负相关,且各自独立预测总生存。
  • PLXNC1是IDO1互作基因中保留最强预后价值者,纳入2基因IDO1-BIN1评分后形成强效免疫基因特征,尤其在接受化疗的患者中预测生存。
  • IDO1低表达与高表达之间及PLXNC1低表达与高表达之间的顶级差异表达基因进一步提升了IDO1的预后价值,提供7基因和10基因免疫特征,高度预测生存并与诊断时AML突变状态相关。

临床怎么用

  • 可考虑将IDO1相关免疫基因特征用于AML患者生存预后评估,尤其在接受化疗的患者中。
  • 支持将免疫生物标志物纳入当前AML分类和预后算法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The contribution of the bone marrow (BM) immune microenvironment to acute myeloid leukemia (AML) development is well-known, but its prognostic significance is still elusive. Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulated by the BIN1 proto-oncogene, is an interferon-γ-inducible mediator of immune tolerance. With the aim to develop a prognostic IDO1-based immune gene signature, biological and clinical data of 982 patients with newly diagnosed, nonpromyelocytic AML were retrieved from public datasets and analyzed using established computational pipelines. Targeted transcriptomic profiles of 24 diagnostic BM samples were analyzed using the NanoString's nCounter platform. BIN1 and IDO1 were inversely correlated and individually predicted overall survival. PLXNC1, a semaphorin receptor involved in inflammation and immune response, was the IDO1-interacting gene retaining the strongest prognostic value. The incorporation of PLXNC1 into the 2-gene IDO1-BIN1 score gave rise to a powerful immune gene signature predicting survival, especially in patients receiving chemotherapy. The top differentially expressed genes between IDO1lowand IDO-1high and between PLXNC1lowand PLXNC1high cases further improved the prognostic value of IDO1 providing a 7- and 10-gene immune signature, highly predictive of survival and correlating with AML mutational status at diagnosis. Taken together, our data indicate that IDO1 is pivotal for the construction of an immune gene signature predictive of survival in AML patients. Given the emerging role of immunotherapies for AML, our findings support the incorporation of immune biomarkers into current AML classification and prognostication algorithms.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ragaini S, Wagner S, Marconi G, et al. An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. Blood Adv. 2022. PMID: 34535017. doi:10.1182/bloodadvances.2021004878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。